Life Sciences industry

EY enables life sciences companies to challenge and reimagine their delivery models, demonstrating greater value in the future healthcare ecosystem.

Biotech

Our biotechnology consulting team brings strategic insights that help biotech companies build value and innovate with confidence.

Real life stories

Biotech case studies

Explore key learnings from our strategic collaboration with leading biotech companies to develop targeted solutions.

How IntraBio's finance transformation fueled its global expansion

EY teams helped the biopharma company solve operational and financial challenges, helping it to focus on groundbreaking drug research.

Read more

Bayer's journey to becoming a preferred partner in clinical trials

The pharmaceutical company sought to improve site relationships and drive industry-leading practices.

Read more

CEO of Bayer AG on mission-first strategy

Strategy in Action, a CEO series by EY-Parthenon.

Learn more

Large language models are planting the seeds of the future

GenAI has helped organize the agronomic knowledge in a way that makes retrieval easy and accessible.

Read more

Industry insights

Biotech thought leadership

Discover key insights and unique perspectives on leading solutions, top biotech trends and industry-transforming issues.

How digital, AI-enabled supply chains can strengthen clinical trials

AI driven, digitally connected supply chains are becoming essential to keeping clinical trials on track amid growing complexities.

Read more

How AI in biopharma drives mission‑focused growth

AI in biopharma must go beyond operational efficiencies and cost savings become a strategic engine driving mission-centric growth and innovation.

Read more

Biotech VC Fundraising Down 2% in 2025, Early-Stage Companies Struggle

Biotech’s 2025 venture capital (VC) fundraising ended at $22.6 billion, down 2% from 2024 but still up 4% compared to the five-year average. Pretty encouraging.

Read more

EY Biotech Beyond Borders Report 2025: Texas Edition

Texas remains a compelling microcosm within the global biotech sector, which is marked by both uncertainty and promise.

Read more

Innovation is moving at an unprecedented speed. Are you staying with it?

Innovation has been the lifeblood of human productivity and value creation since the Industrial Revolution.

Read more

EY Biotech Beyond Borders Report 2025

As biopharma companies face a rapidly changing political landscape, we explore industry performance over the last year, including strategies that will position companies for long-term success.

Read more

Key steps for improving biopharma expansion into new markets

As biopharma companies look to new markets for growth, leaders need to tailor their expansion efforts to the nuances of each market.

Read more

New year, new hope for the biotech IPO market

Could we finally be witnessing the reopening of the biotech IPO window?

Read more

The BIOSECURE Act is now law. Are you ready?

After years of negotiations, the BIOSECURE Act was enacted into law in a version that reduces some of the anticipated disruption to the life sciences sector.

Read more

How can the life sciences industry go from fragmentation to creating a new fabric for innovation?

With the festive season on the horizon and the New Year also shaping up to be exciting, I’m not just looking forward to Santa and mince pies

Read more

Where to find us

Biotech events and webcasts

Watch for us in market at key industry events or join the conversation via our webcast platform as EY thought leaders share new insights on the latest pharma trends.

Bio-IT World Expo
May 19-21, 2026
Boston, MA
Read more

Bio International Convention
June 22-25, 2026
San Diego, CA
Read more

Biotech contact

Arda Ural, PhD EY Americas Life Sciences Sector Leader Ernst & Young LLP
Subscribe

Pharma

From pharmaceutical M&A to capital optimization and more, we empower the pharmaceutical industry to drive innovation and growth.

Real life stories

Pharma case studies

How Bristol Myers Squibb overhauled working capital to fund its future

An EY-Parthenon team helped BMS establish a cash leadership office as part of an award-winning Treasury transformation. Learn more in this case study.

Read more

How Sigma, an Australian pharmaceutical company, transformed its supply chain

Discover how EY teams helped Sigma simplify and standardize to boost availability and cut inventory by 20%.

Read more

Accelerated access to novel cancer therapies at Moores Cancer Center

Moores Cancer Center accelerated activation of high-priority clinical trials by leveraging the EY Clinical Trial Fast Lane solution.

Read more

How tech and trust transformed a tax operating model

Global pharmaceutical player Boehringer Ingelheim is reimagining its tax operating model to boost quality and efficiency.

Read more

How a B2B company drove engagement by transforming its D2C platform

Merck Animal Health modernized its HomeAgain e-commerce site to offer customers a robust online experience that drives growth and expansion.

Read more

What going digital means for Takeda

Takeda Business Solutions fast-tracked its digitalization evolution through an innovative top-down and bottom-up journey.

Read more

How confident are you turning your vision into value?

Our deep experience helped a pharma company establish a global footprint.

Learn more

Industry insights

Pharma thought leadership

Discover key insights and unique perspectives on leading solutions and top pharma industry trends.

How biopharmas can better integrate pre-commercial acquisitions

Acquiring pre-commercial assets is critical to fill biopharma development pipelines. The deals require a tailored integration approach.

Read more

How AI in biopharma drives mission-focused growth

AI in biopharma must go beyond operational efficiencies and cost savings become a strategic engine driving mission-centric growth and innovation.

Read more

How AI can form the foundation for an always-on biopharma deal radar

AI can help biopharma companies identify M&A targets to build up their R&D pipelines as they face a “patent cliff” for existing treatments.

Read more

EY Firepower Report: Life Sciences Dealmaking and M&A Growth Strategy

The EY 2026 Firepower M&A report finds life sciences companies recognizing the need to accelerate their dealmaking strategies to succeed in an increasingly competitive environment.

Read more

How to accelerate growth through commercial transformation in pharma

Facing intensifying pressure to drive stronger customer engagement, growth and efficiency, organizations in the industry must evolve.

Read more

How to make account-based selling work for pharma

Learn more about how EY teams can help you respond to changes that you can’t afford to ignore.

Read more

How to enhance traceability in the life sciences supply chain

As the need for enhanced traceability intensifies, modern solutions can help organizations drive patient safety and product integrity.

Read more

How next-generation CRM will reshape the life sciences commercial model

CRM must evolve from analogue maps to real-time GPS for pharma. Unlock deeper insights — transform your customer engagement now.

Read more

Innovation is moving at an unprecedented speed. Are you staying with it?

Innovation has been the lifeblood of human productivity and value creation since the Industrial Revolution.

Read more

When and how to use GenAI in late-stage clinical development

GenAI and related tools can help improve the design of clinical trials and speed data gathering and regulatory reporting.

Read more

How to reach gold-standard operations in pharmaceutical manufacturing

The “golden batch” approach is poised to revolutionize pharma manufacturing by setting the standard for an ideal production run.

Read more

How biopharma can get the right mix of people and tech for launch success

Facing a challenging commercial environment, biopharma companies need to embrace an end-to-end, AI-driven strategy to succeed.

Read more

How AI can support decision-making in drug development portfolios

For the pharmaceutical industry, AI can be a powerful tool to drive better-informed asset portfolio decisions.

Read more

How real-time release (RTR) can transform pharmaceutical manufacturing

RTR has significant potential, but pharmaceutical manufacturers looking to adopt it must first meet several prerequisites.

Read more

Drive commercial success by effectively navigating loss of exclusivity

When patent expiration looms, strategic planning across functions can help pharma leaders increase value.

Read more

Why ‘AI by design’ is foundational to pharmaceutical manufacturing

To unlock the potential of AI, pharmaceutical manufacturers need a robust data foundation to drive success.

Read more

Life sciences dealmaking remains, with early-stage deals and China’s rise as a biotech hub continuing to take center stage

RTR has significant potential, but pharmaceutical manufacturers looking to adopt it must first meet several prerequisites.

Read more

How can the life sciences industry go from fragmentation to creating a new fabric for innovation?

Life sciences is no longer just about molecules and microscopes. It’s about data, digital ecosystems and the ability to connect dots at lightning speed.

Read more

Why it’s time for pharma leaders to rethink quality

Pharmaceuticals manufacturers are facing increasing compliance regulations and challenges from global production.

Read more

Where to find us

Pharma events and webcasts

Watch for us in market at key industry events or join the conversation via our webcast platform as EY thought leaders share new insights on the latest pharma trends.

ASEMBIA Summit
Las Vegas NV
April 26-30 2026
Learn more

2026 PMSA Annual Conference
May 3-6, 2026
New Orleans, LA
Learn more

Pharma contact

Arda Ural, PhD EY Americas Life Sciences Sector Leader Ernst & Young LLP
Subscribe

MedTech

We work closely with leading and emerging companies across the medical technology industry in key areas such as M&A and supply chain.

Real life stories

MedTech case studies

Explore key learnings from our strategic collaboration with leading pharma companies to develop targeted solutions.
The state of MedTech 2025
Hear from John Babitt, EY Global MedTech Leader, as he shares important highlights on the state of the industry.
Learn more
How Medtronic’s optimized supply chain gets products to patients in need
A supply chain transformation enabled more personalized care for over 78 million patients.
Read more

Industry insights

MedTech thought leadership

Discover key insights and unique perspectives on leading solutions and top MedTech industry trends.
Pulse of the MedTech Industry Report 2025
Reigniting growth and expanding markets.
Read more
Investing in innovation: unlocking value in MedTech
For top performers, R&D investments fuel growth, increase investor confidence and unlock total shareholder return.
Read more
Pursuing the right deals now to deliver value into the future
Discussion with executive leaders from top Life Sciences companies.
Read more
How organizations can deliver medical device security the care it needs
Many smart medical devices in health care today are not designed with security in mind, exposing sensitive data to risk.
Read more

Where to find us

MedTech events and webcasts

Watch for us in market at key industry events or join the conversation via our webcast platform as EY thought leaders share new insights on the latest MedTech industry trends.
The MedTech Conference
October 18-21, 2026
Boston, MA
Learn more

MedTech contact

John Babitt EY Global MedTech Leader Ernst & Young LLP
Subscribe

Key research and reports

Pulse of the MedTech Industry Report 2025

Learn how MedTech companies are reigniting growth and expanding markets, with the industry's annual revenue growing for the seventh straight year, reaching almost US$600 billion for the first time.

Access report

EY Firepower Report: Life Sciences Dealmaking and M&A Growth Strategy

The EY 2026 Firepower M&A report finds life sciences companies recognizing the need to accelerate their dealmaking strategies to succeed in an increasingly competitive environment.

Access report

EY Biotech Beyond Borders Report 2025

As biopharma companies face a rapidly changing political landscape, we explore industry performance over the last year, including strategies that will position companies for long-term success.

Access report

Life Sciences industry

How next-generation CRM will reshape the life sciences commercial model

CRM must evolve from analogue maps to real-time GPS for pharma. Unlock deeper insights—transform your customer engagement now. Read more.

Discover our curated library of other life sciences insights, from R&D to finance, innovation and more.

Knowledge sharing and news (7)

Skip

west

Decoding CMS drug pricing models, benchmarks and MFN alignment

Decoding CMS drug pricing models, benchmarks and MFN alignment

How an authentic journey brought leadership success

How an authentic journey brought leadership success

The dividend age: How AI is turning promise into payoff

The dividend age: How AI is turning promise into payoff

Enhance supply chain efficiency and autonomous operations with innovative solutions from EY and NVIDIA teams

Enhance supply chain efficiency and autonomous operations with innovative solutions from EY and NVIDIA teams

Transforming supply chain strategy with AI

Transforming supply chain strategy with AI

How Bayer is unearthing agronomy's future with generative AI

How Bayer is unearthing agronomy's future with generative AI

Why some tax functions use data effectively while others struggle

Why some tax functions use data effectively while others struggle

east

Digital Spotlight

Featured webcasts and other media. Registration may be required.

Macro Bites: Life sciences adapt to a new economic paradigm

Gregory Daco and Ranu Carroll discuss a new economic paradigm, supply chain dynamics, imports of active pharmaceutical ingredients and what we’re hearing from clients.

Watch video

Tectonic shifts in operating environment

Shifting environments: Geopolitics and the US Life Sciences sector

Watch the replay

How smaller, smarter deals will help life sciences shape the future with confidence

Hear from a panel of industry leaders as we explore the findings from our 13th annual EY Firepower Report on life sciences dealmaking and M&A growth strategy.

Watch the replay

Tariffs are here: what companies need to do now

Get updates from EY tax and trade professionals for an update on what’s happening in trade, the latest on tariffs and steps companies should consider taking now.

Watch the replay

The future state of transfer pricing controversy for life sciences

Key actions that companies can be taking today to navigate a rapidly intensifying global transfer pricing controversy environment more effectively.

Watch the replay

Solutions that work in practice, not just on paper

Learn how a pharma company’s growth and operational strategy helped establish a global footprint.

Watch now

Creating new life sciences revenue models

Venture building can help life sciences companies drive innovation in the face of the patent cliff.

Watch now

More ways EY can help you

Explore our life sciences and related capabilities.

Consulting

Realize business transformation via people, technology and innovation.

Learn more

Cybersecurity

Build a more secure, compliant and resilient cybersecurity posture.

Learn more

Supply Chain

Create supply chains that grow, optimize and protect operations.

Learn more

EY Clinical Trial Fast Lane

Accelerate clinical trial site activation.

Learn more

EY Smart Reviewer

Leverage AI and machine learning to review promotional materials.

Learn more

Omnichannel Customer Experience

Evolve customer engagement models.

Learn more

AI insights

Explore our global insights that look at how you can build confidence in AI, drive exponential value throughout your organization and deliver positive human impact.

Learn more

Quality Analytics and Decision Support

Leverage actionable insights to improve quality across operations.

Learn more

Biopharma Launch Edge

Discover faster, simpler, more successful launch processes.

Learn more

Transformative Strategy and Transactions

Transform your strategic vision into reality with EY-Parthenon.

Learn more

Pharma Promotional Content Management Services

Transform end-to-end processes and improve results.

Learn more

Health Policy, Washington Council Ernst & Young

Informing strategic decision-making and creating meaningful policy change

Learn more

The team

Linda Hill

EY Global and Americas Consumer and Health Leader

Strategic leader focused on innovation. Collaborative team builder. Champion for audit quality. Client-centric problem solver. Avid reader. Ambitious hiker. Occasional middle school sports coach.

St. Louis, MO, United States

Arda Ural, PhD

EY Americas Life Sciences Leader

Frequent speaker about biopharmaceutical strategy at industry conferences. Married father of two.

New York, NY, United States

Richard Ramko

EY Americas Life Sciences Sector and Biotechnology Leader

Experienced life sciences advisor. Serves on charitable boards.

San Mateo – Silicon Valley, CA, United States

Diana Hoff

EY Americas Life Sciences Sector Leader, Partner, Ernst & Young LLP

Strategic executive. Creative and pragmatic problem-solver. Empathetic leader.

Philadelphia, PA, United States

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.